Pharma BD Deal Intelligence
Thermo Fisher Scientific Inc. / Clario Holdings, Inc.
2025 · Acquisition/Merger · $9.4B · Pending
Thermo Fisher Scientific agreed to acquire Clario Holdings, a provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital with Novo Holdings and Cinven. Consideration is USD 8.875 billion in cash at closing plus USD 125 million deferred and up to USD 400 million contingent, for up to USD 9.4 billion total. Clario is to join Thermo Fisher's Laboratory Products and Biopharma Services segment; the deal was expected to close by mid-2026 subject to regulatory approvals. Post-close status not verified as of this ingest.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Oct 29, 2025
- Deal value $9.4B
- Deal type Acquisition/Merger
- Key assets Clario endpoint data and clinical-trial technology platform
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Thermo Fisher Scientific Inc. deals